Applied BioCode

Overview

Applied BioCode, founded in 2008 and based in the United States, operates within the manufacturing sector, specifically focusing on test and measurement equipment as well as electrical and electronic manufacturing. The company has developed expertise in biotechnology and pharmaceuticals, particularly in the area of molecular diagnostics. A notable publication from Applied BioCode is a research article evaluating the BioCode GPP (Gastrointestinal Pathogen Panel) for the syndromic molecular detection of gastrointestinal pathogens from stool specimens. This multicenter study highlights the effectiveness of the BioCode GPP in detecting various bacterial, viral, and protozoan pathogens, demonstrating its potential advantages over traditional microbiological methods, which often have limited sensitivity and longer turnaround times. The findings indicate that the BioCode GPP can significantly enhance the detection rates of common gastrointestinal pathogens, thereby contributing to improved clinical outcomes. With a workforce of 51 to 200 employees and reported revenue of approximately $10.3 million, Applied BioCode continues to advance in the field of molecular diagnostics while addressing critical healthcare challenges.

Industry